CytomX Therapeutics (CTMX) Equity Ratio (2016 - 2025)
Historic Equity Ratio for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 0.68.
- CytomX Therapeutics' Equity Ratio rose 50214.31% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year increase of 50214.31%. This contributed to the annual value of 0.0 for FY2024, which is 9839.1% up from last year.
- Latest data reveals that CytomX Therapeutics reported Equity Ratio of 0.68 as of Q3 2025, which was up 50214.31% from 0.68 recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Equity Ratio registered a high of 0.68 during Q2 2025, and its lowest value of 0.41 during Q2 2023.
- In the last 5 years, CytomX Therapeutics' Equity Ratio had a median value of 0.17 in 2024 and averaged 0.04.
- As far as peak fluctuations go, CytomX Therapeutics' Equity Ratio plummeted by 2420487.12% in 2022, and later skyrocketed by 50214.31% in 2025.
- Quarter analysis of 5 years shows CytomX Therapeutics' Equity Ratio stood at 0.0 in 2021, then crashed by 24204.87% to 0.33 in 2022, then increased by 28.46% to 0.24 in 2023, then soared by 98.39% to 0.0 in 2024, then surged by 18036.85% to 0.68 in 2025.
- Its Equity Ratio was 0.68 in Q3 2025, compared to 0.68 in Q2 2025 and 0.25 in Q1 2025.